Solasia Announces Launch of Darvias® in Japan

News provided bySolasia Pharma K.K.
August 23, 2022 11:35
TOKYO--(Business Wire / Korea Newswire) August 23, 2022 -- Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd. (TOKYO:4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220822005303/en/

Website: http://www.solasia.co.jp/en/

View Korean version of this release

Contact

Solasia Pharma K.K.
Toyokazu Ohata, Public Relations and Investor Relations
+81 3 5843 8046 (TOKYO)
info@solasia.co.jp

This news is a press release announced by the provider. The media can use this material for reporting. Korea Newswire is committed to verifying the reliability and transparency of providers and eliminating content errors in accordance with editorial guidelines. If you have any issues with the press release, please let us know.

News provided bySolasia Pharma K.K.

배포 채널